No clinically significant pharmacokinetic interactions between dolutegravir and daclatasvir in healthy adult subjects

BACKGROUND: Daclatasvir (DCV) is an NS5A replication complex inhibitor recently approved for chronic hepatitis C virus treatment. METHODS: To assess drug interactions between the HIV integrase strand transfer inhibitor dolutegravir (DTG) and DCV, subjects were randomized into 1 of 2 sequences in an...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:BMC Infect Dis
Egile Nagusiak: Ross, Lisa L., Song, Ivy H., Arya, Niki, Choukour, Mike, Zong, Jian, Huang, Shu-Pang, Eley, Timothy, Wynne, Brian, Buchanan, Ann M.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2016
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4957413/
https://ncbi.nlm.nih.gov/pubmed/27450277
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12879-016-1629-5
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak